Business Context and Reporting Period
Company: Dr. Reddy's Laboratories Ltd.
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: Second Quarter (Q2) of Fiscal Year 2010, ended September 30, 2009.
Business Overview: An emerging global pharmaceutical company with three core businesses: Pharmaceutical Services and Active Ingredients (PSAI), Global Generics, and Proprietary Products. Key markets include India, the US, UK, Germany, and Russia.
Key Financial Metrics
| Metric | Q2 FY10 (Rs. Million) | Q2 FY10 (USD Million) | Q2 FY09 (Rs. Million) | Q2 FY09 (USD Million) |
|---|---|---|---|---|
| Revenue | 18,368 | 382 | 16,151 | 336 |
| Gross Profit | 8,719 | 181 | 7,964 | 166 |
| Operating Income | 2,545 | 53 | 1,765 | 37 |
| EBITDA | 3,797 | 79 | 2,500 (approx) | 52 |
| Profit After Tax (PAT) | 2,173 | 45 | 1,052 | 22 |
| Diluted EPS | Rs. 12.8 | $0.3 | Rs. 6.2 | $0.1 |
Liquidity and Balance Sheet (as of Sept 30, 2009):
- Cash and Cash Equivalents: Rs. 6,149 million ($128 million)
- Loans and Borrowings: Rs. 14,668 million ($305 million)
- Equity: Rs. 45,649 million ($949 million)
Material Changes vs. Prior Period
- Revenue Growth: Consolidated revenue increased 14% year-over-year (YoY) to Rs. 18.4 billion, driven primarily by the Global Generics segment.
- Profitability Surge: PAT grew 106% YoY to Rs. 2.2 billion. Adjusted PAT growth (excluding prior year exceptions) was 79%.
- EBITDA Expansion: EBITDA rose 51% YoY to Rs. 3.8 billion.
- Segment Performance:
- Global Generics: Revenue up 14% to Rs. 12.7 billion. North America grew 36% and Russia grew 39%. Europe declined 13% due to pricing pressure and tender results in Germany.
- PSAI: Revenue up 11% to Rs. 5.4 billion, aided by rupee depreciation.
- Margin Impact: Gross margin decreased from 49% to 47% due to one-time inventory provisions (Rs. 6 million in Germany, $4 million in US). Adjusted margins were 51%.
- Finance Costs: Net finance income improved significantly from a net cost of Rs. 482 million in Q2 FY09 to net income of Rs. 208 million in Q2 FY10, largely due to a forex gain of Rs. 244 million.
Guidance, Outlook, and Risks
Management Commentary & Strategy:
- Product Launches: Launched 39 new generic products and filed 24 new product registrations in the quarter. Launched Strea TM C10 and A15 (aesthetics) in India.
- Sustainability: Joined the American Chemical Society Green Chemistry Institute Pharmaceutical Roundtable to integrate green chemistry principles.
- Corporate Governance: Appointed Dr. Ashok Ganguly as an additional director.
Risks and Contingencies:
- German Market: Ongoing reforms and public health insurance tenders in Germany may impact the subsidiary betapharm's business; results of major tenders were pending.
- Regulatory Pipeline: 62 ANDAs pending USFDA approval (27 Para IVs, 16 FTFs).
- Forward-Looking Statements: Results may differ due to economic conditions, market acceptance, and technological changes.
Investor Verification Checklist
- German Tender Outcomes: Verify the final results of the public health insurance tenders in Germany and their impact on betapharm revenue.
- Inventory Provisions: Confirm the nature and recurrence of the Rs. 6 million (Germany) and $4 million (US) inventory write-downs.
- ANDA Approvals: Monitor the approval status of the 62 pending ANDAs, particularly the 27 Paragraph IV challenges.
- Currency Exposure: Assess the sustainability of the forex gain (Rs. 244 million) given the volatility of the Rupee against the Dollar.
- Sequential Growth: Validate the 11% sequential revenue growth excluding sumatriptan to ensure organic momentum.